Current affairs

Which vaccine provides more protection against the Delta plus variant of Covid? ICMR study reveals!

By alagu, 03 August, 2021
Delta Plus variant, COVID-19, Covaxin, India

As India is ramping up the vaccination drive to beat the Covid-19 pandemic with the Union government has been in the process of rolling out the vaccination programs for the minors below the age of 18, the latest study conducted by the Indian Council of Medical Research (ICMR) has revealed which vaccine provides more protection against the Delta Plus variant of the pandemic. 

Delta variant has been declared as the variant of concern by the World Health Organization after it has put various countries in a whammy with rising Covid-19 infections. While the countries are combating the severe mutant of Coronavirus, the ICMR study has poured a relief through its study of revealing the vaccine which provides protection against the variant. 

According to the study, Bharat Biotech's Covid-19 vaccine, Covaxin, provides protection against the Dela Plus variant. On Monday, the ICMR took to Twitter and said that its study shows Covaxin is effective in Delta, Delta AY.1 (Delta Plus), and B.1.617.3 variants." According to ICMR, Covaxin, one of India's flagship Covid-19 vaccines, has been found to provide 65.2 per cent protection against the Delta variant in a double-blind, randomized, multicenter, phase 3 clinical trial. 

In the study, ICMR has said, "Here, we have evaluated the IgG antibody titer and neutralizing potential of sera of Covid-19 naive individuals full doses of BBV152 vaccine, Covid-19 recovered cases with full dose vaccines and breakthrough cases post-immunization BBV152 vaccines against Delta, Delta AY.1, and B.1.617.3." The medical council has said that the results reveal Covaxin neutralizes the Delta, Delta AY.1, and B.1.617.3 variants effectively. 

The ICMR study has been published on BioRxiv, a pre-print server and it is yet to be peer-reviewed. It must be noted that Bharat Biotech, while concluding the final analysis of the efficacy of Covaxin from phase-3 trials on July 3, said that Covaxin has demonstrated 77.8 per cent effectiveness against symptomatic Covid-19 and 65.2 per cent protection against the B.1.617.2 Delta variant. 

The Delta Plus variant of Covid-19 was first detected in India in April 2021 and subsequently reported in 20 other countries. In May, the World Health Organization has tagged B.1.617.2 strain as the Delta variant of the Novel Coronavirus and it was later identified as one of the main reasons for the second wave of the Covid-19 pandemic that has let the country witnessed major devastations. As the variant was widespread across the globe, WHO has declared it as a variant of concern. 
 

 

You may also like

Comments